Since the onset of the coronavirus pandemic, some companies have been trying to do their part in helping the world get back to some sense of normalcy. As scientists speculate on the possibility COVID-19 becomes another recurring disease humans learn to live with, much like the flu, delivery giant UPS says it's committed to the continued safe distribution of vaccines around the world.
"The world is now vaccinating roughly six million people a day. That'll be 5.4 years before we get to 75 percent of the world's population," Scott Price, head of international operations for UPS, told Cheddar.
"What I can tell you is that given the size and the scope of the world's population and in our network, we're always going to be prepared for the capacity needs to get this vaccine around the world," he added.
The company's services aren't just limited to the needs of the United States. While the AstraZeneca vaccine has not been cleared for use in the U.S., UPS has worked closely with other countries, South Korea in particular, in distribution efforts. Price said the company is willing to transport any vaccine to any place in need.
UPS Healthcare and the UPS Foundation have also donated $3 million to COVID vaccination efforts.
"Distribution is really critical when it comes to vaccines. We've been doing healthcare distribution. We have a pretty substantial segment, but you know the ultra-low temperature required on these vaccines is what makes this one particularly unique," Price said. "Now, we have cold storage capability, so as part of our donation, that $3 million, part of it is just capacity of that ultra-low temperature."
With the company delivering nearly 25 million packages every day, Price said UPS has "plenty of capacity" to ensure the safe delivery of vaccines worldwide.
"We have to continue to drive solutions in manufacturing so that we're able to get these into the arms of citizens around the world," he explained.
YouTube will offer creators a way to rejoin the streaming platform if they were banned for violating COVID-19 and election misinformation policies that are no longer in effect.
Lukas Alpert of MarketWatch explores how networks, brands, and ad buyers absorb the shockwaves when late‑night show hosts are suddenly cut — and brought back.
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
